Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients.

Hepatology (Baltimore, Md.) - 1 Jul 2011

Wagner Frank, Thompson Robert, Kantaridis Constantino, Simpson Paul, Troke Philip J F, Jagannatha Shyla, Neelakantan Srividya, Purohit Vivek S, Hammond Jennifer L

Abstract excerpt

UNLABELLED: More effective and better-tolerated therapies are needed for chronic hepatitis C virus (HCV) infection. Among the direct-acting anti-HCV agents in development is the nonstructural 5B protein (NS5B polymerase) non-nucleoside inhibitor filibuvir. We investigated the antiviral activity,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Double-Blind Method
Share to Interferon-alpha
Share to Interferon alpha-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polyethylene Glycols

Share to Pyrones

Share to Ribavirin

Share to Triazoles

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 21488067
DOI: 10.1002/hep.24342

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21488067-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients.PMID 21488067Read ↗

A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV.Semantic proximity Read ↗

1052 ANTIVIRAL ACTIVITY OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN FOR 28 DAYS IN TREATMENT NAIVE PATIENTS CHRONICALLY INFECTED WITH HCV GENOTYPE 1Semantic proximity Read ↗

Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients.Semantic proximity Read ↗

Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.Semantic proximity Read ↗

Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment.Semantic proximity Read ↗

A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1.Semantic proximity Read ↗

Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir.Semantic proximity Read ↗

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.Semantic proximity Read ↗

Computational study on the drug resistance mechanism of HCV NS5B RNA-dependent RNA polymerase mutants V494I, V494A, M426A, and M423T to Filibuvir.Semantic proximity Read ↗

Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase.Semantic proximity Read ↗

Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.